Irmina Diala

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers”.

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Cancer Discovery(2020)10.1158/2159-8290.cd-20-0215

N/A

0DataRank · unranked

293 citations

Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai +44 more

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non–Small Cell Lung Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-1844

N/A

0DataRank · unranked

42 citations

Mari Kuraguchi, Man Xu, Andrew Portell, Luke J. Taus, Irmina Diala +17 more

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening

Biomedicines(2021)10.3390/biomedicines9070740

N/A

0DataRank · unranked

19 citations

Huey Liu, Troy Pearson, Toshiaki Iwase, Jon A. Fuson, Alshad S. Lalani +6 more

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

npj Breast Cancer(2021)10.1038/s41523-021-00274-0

N/A

0DataRank · unranked

11 citations

Carolina Gutiérrez, Vidyalakshmi Sethunath, Sepideh Mehravaran, Mario Giuliano, Martin J. Shea +16 more